Targovax ASA: Invitation to online presentation at 10:00 CET 2 December
Oslo, Norway, 2 December 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET.With reference to the press release issued 1 December 2020 (see link here ), Targovax will present data from its phase 1 trial combining ONCOS-102